Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 9/20 | 0.48 |
| ▸ | LCK | P06239 | 3/20 | 0.48 |
| ▸ | EGFR | P00533 | 2/20 | 0.48 |
| ▸ | BTK | Q06187 | 2/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | FER | P16591 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.35 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 2/20 | 0.35 |
| ▸ | JAK1 | P23458 | 2/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.35 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23081111 | 0.87 | JAK3 (0.48) | JAK3LCKEGFRBTKLRRK2 | |
| SCHEMBL18283775 | 0.83 | JAK3 (0.54) | JAK3LCKEGFRBTK | |
| SCHEMBL23081221 | 0.83 | JAK3 (0.45) | JAK3LCKEGFRBTKLRRK2 | |
| SCHEMBL18283585 | 0.82 | JAK3 (0.65) | JAK3LCKEGFRBTKSYK | |
| SCHEMBL28857028 | 0.81 | RET (0.47) | JAK3LCKEGFRBTKPIK3CD | |
| SCHEMBL18283764 | 0.79 | JAK3 (0.51) | JAK3LCKEGFRBTK | |
| SCHEMBL18283449 | 0.78 | JAK3 (0.47) | JAK3LCKEGFRBTKJAK2 | |
| SCHEMBL18296278 | 0.78 | JAK3 (0.53) | JAK3LCKEGFRBTKJAK2 | |
| SCHEMBL18296104 | 0.78 | PIK3CD (0.50) | JAK3LCKBTKPIK3CDPIK3R1 | |
| SCHEMBL23081017 | 0.77 | JAK3 (0.61) | JAK3LCKEGFRBTKLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070748-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2021-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070748-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | BTK, LYN, LCK | JAK3 64/4885LCK 3/4885EGFR 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.